One type of nanoparticle currently in development engages in “active targeting,” or targeting drugs to cancer cells by attaching them to a molecule that the cancer cell is receptive to.
GenVec Receives Orphan Drug Designation, $22M Development Deal
GenVec’s experimental drug to treat pancreatic cancer has been granted orphan drug status by the U.S. Food and Drug Administration.
The Key to Stopping Colon Cancer?
Scientists in Switzerland may have found a way to inhibit the growth of colon cancer in humans, says a new study published in EMBO Molecular Medicine.
